144 related articles for article (PubMed ID: 29250742)
61. A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
VanderWeele DJ; Kocherginsky M; Munir S; Martone B; Sagar V; Morgans A; Stadler WM; Abdulkadir S; Hussain M
Clin Genitourin Cancer; 2022 Dec; 20(6):575-580. PubMed ID: 36210299
[TBL] [Abstract][Full Text] [Related]
62. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
Bianchini D; Omlin A; Pezaro C; Lorente D; Ferraldeschi R; Mukherji D; Crespo M; Figueiredo I; Miranda S; Riisnaes R; Zivi A; Buchbinder A; Rathkopf DE; Attard G; Scher HI; de Bono J; Danila DC
Br J Cancer; 2013 Nov; 109(10):2579-86. PubMed ID: 24169353
[TBL] [Abstract][Full Text] [Related]
63. Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer.
Holder SL; Drabick J; Zhu J; Joshi M
Cancer Biol Ther; 2015; 16(2):207-9. PubMed ID: 25756508
[TBL] [Abstract][Full Text] [Related]
64. The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.
Katsogiannou M; Andrieu C; Baylot V; Baudot A; Dusetti NJ; Gayet O; Finetti P; Garrido C; Birnbaum D; Bertucci F; Brun C; Rocchi P
Mol Cell Proteomics; 2014 Dec; 13(12):3585-601. PubMed ID: 25277244
[TBL] [Abstract][Full Text] [Related]
65. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Baylot V; Katsogiannou M; Andrieu C; Taieb D; Acunzo J; Giusiano S; Fazli L; Gleave M; Garrido C; Rocchi P
Mol Ther; 2012 Dec; 20(12):2244-56. PubMed ID: 22893039
[TBL] [Abstract][Full Text] [Related]
66. Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer.
Matsui Y; Hadaschik BA; Fazli L; Andersen RJ; Gleave ME; So AI
Mol Cancer Ther; 2009 Aug; 8(8):2402-11. PubMed ID: 19625496
[TBL] [Abstract][Full Text] [Related]
67. Understanding symptomatic experience, impact, and emotional response in recently diagnosed metastatic castration-resistant prostate cancer: a qualitative study.
Burbridge C; Randall JA; Lawson J; Symonds T; Dearden L; Lopez-Gitlitz A; Espina B; McQuarrie K
Support Care Cancer; 2020 Jul; 28(7):3093-3101. PubMed ID: 31659445
[TBL] [Abstract][Full Text] [Related]
68. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer.
Yu EY; Hancock ML; Aronson W; Flaig T; Belkoff L; Tutrone R; Taylor R; Hardigan PC; Getzenberg RH
Clin Genitourin Cancer; 2020 Dec; 18(6):436-443. PubMed ID: 32321673
[TBL] [Abstract][Full Text] [Related]
69. Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.
Schaffer EM; Basch EM; Schwab GM; Bennett AV
Clin Trials; 2021 Aug; 18(4):408-416. PubMed ID: 33884929
[TBL] [Abstract][Full Text] [Related]
70. Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer.
Ziouziou H; Paris C; Benizri S; Le TK; Andrieu C; Nguyen DT; Appavoo A; Taïeb D; Brunel F; Oueslati R; Siri O; Camplo M; Barthélémy P; Rocchi P
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33925528
[TBL] [Abstract][Full Text] [Related]
71. Continuous IV Infusion of 5-Flourouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.
Manogue C; Fleming W; Ledet E; Jaeger E; Layton J; Barata P; Lewis B; Sartor O
Clin Genitourin Cancer; 2022 Dec; 20(6):586-590. PubMed ID: 35869001
[No Abstract] [Full Text] [Related]
72. Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial.
Nielsen TK; Højgaard M; Andersen JT; Jørgensen NR; Zerahn B; Kristensen B; Henriksen T; Lykkesfeldt J; Mikines KJ; Poulsen HE
Transl Androl Urol; 2017 Jun; 6(3):517-528. PubMed ID: 28725594
[TBL] [Abstract][Full Text] [Related]
73. Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.
Ziouziou H; Andrieu C; Laurini E; Karaki S; Fermeglia M; Oueslati R; Taieb D; Camplo M; Siri O; Pricl S; Katsogiannou M; Rocchi P
Oncotarget; 2018 Jun; 9(47):28797. PubMed ID: 29983898
[TBL] [Abstract][Full Text] [Related]
74. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Hussain M; Daignault-Newton S; Twardowski PW; Albany C; Stein MN; Kunju LP; Siddiqui J; Wu YM; Robinson D; Lonigro RJ; Cao X; Tomlins SA; Mehra R; Cooney KA; Montgomery B; Antonarakis ES; Shevrin DH; Corn PG; Whang YE; Smith DC; Caram MV; Knudsen KE; Stadler WM; Feng FY; Chinnaiyan AM
J Clin Oncol; 2018 Apr; 36(10):991-999. PubMed ID: 29261439
[TBL] [Abstract][Full Text] [Related]
75. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
Heller G; McCormack R; Kheoh T; Molina A; Smith MR; Dreicer R; Saad F; de Wit R; Aftab DT; Hirmand M; Limon A; Fizazi K; Fleisher M; de Bono JS; Scher HI
J Clin Oncol; 2018 Feb; 36(6):572-580. PubMed ID: 29272162
[TBL] [Abstract][Full Text] [Related]
76. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).
Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO
Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182
[TBL] [Abstract][Full Text] [Related]
77. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
[TBL] [Abstract][Full Text] [Related]
78. A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.
Bouman-Wammes EW; van den Berg HP; de Munck L; Beeker A; Smorenburg CH; Vervenne WL; Coenen JLLM; Verheul HMW; Gerritsen WR; Van den Eertwegh AJM
Eur J Cancer; 2018 Feb; 90():1-9. PubMed ID: 29268139
[TBL] [Abstract][Full Text] [Related]
79. Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.
Yang DD; Muralidhar V; Mahal BA; Nguyen PL; Devlin PM; King MT; Orio PF
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):53-58. PubMed ID: 29254781
[TBL] [Abstract][Full Text] [Related]
80. Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Thomas A; Redon CE; Sciuto L; Padiernos E; Ji J; Lee MJ; Yuno A; Lee S; Zhang Y; Tran L; Yutzy W; Rajan A; Guha U; Chen H; Hassan R; Alewine CC; Szabo E; Bates SE; Kinders RJ; Steinberg SM; Doroshow JH; Aladjem MI; Trepel JB; Pommier Y
J Clin Oncol; 2018 Jun; 36(16):1594-1602. PubMed ID: 29252124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
